Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 701–800 of 1,017
Bennett, L., Zhao, Z., Barber, B. R., Zhou, X., Peeters, M., Zhang, J., Xu, F., Wiezorek, J. S., & Douillard, J.-Y. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.409 · Cited by 64
“In metastatic disease, in addition to delaying disease progression, maintenance of health-related quality of life (HRQoL) – a measure of how a disease or its treatment affects a persons’ physical, emotional and social well-being (Cella, 1995) – is a Received 6 June 2011; revised 9 September 2011; accepted 13 September…”
BackgroundInfluentialWestley, R., & May, F. E. B. (2013) · International Journal of Endocrinology · doi:10.1155/2013/632461 · Cited by 70
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Sánchez-Muñoz, A., Gallego, E., de Luque, V., Pérez-Rivas, L. G., Vicioso, L., Ribelles, N., Lozano, J., & Alba, E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-136 · Cited by 59
Review of systemic therapies for locally advanced and metastatic rectal cancer.
Yaffee, P. M., Osipov, A., Tan, C. R. C., Tuli, R., & Hendifar, A. E. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2014.112 · Cited by 58
“The CRYSTAL trial opened the door for cetuximab as a first line therapy (107).”
BackgroundRosa, M. D., Rega, D., Costabile, V., Duraturo, F., Niglio, A., Izzo, P., Pace, U., & Delrio, P. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16659790 · Cited by 69
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
Fuchs, H., Niesler, N., Trautner, A., Sama, S., Jerz, G., Panjideh, H., & Weng, A. (2017) · Biomedicines · doi:10.3390/biomedicines5020014 · Cited by 68
Therapeutic inhibition of SGK1 suppresses colorectal cancer
Liang, X., Lan, C. B., Jiao, G., Fu, W., Long, X., An, Y., Wang, K., Zhou, J., Chen, T., Li, Y., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.184 · Cited by 60
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 58
Scaria, B., Sood, S., Raad, C., Khanafer, J., Jayachandiran, R., Pupulin, A., Grewal, S. S., Okoko, M., Arora, M., Miles, L., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228480 · Cited by 64
“A study revealed that curcumin blocked cell proliferation through the induction of ROS generation and downregulation of E2F4, cyclin A, p21, and p27 [122].”
BackgroundResistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 66
Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers
Lan, Y., Lin, J., Lin, C., Yang, S., Lin, C., Wang, H., Chen, W., Lin, T., Jiang, J., & Chang, S. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23895 · Cited by 62
“, New York, NY), which is a chimeric monoclonal antibody that targets the extracellular domain of EGFR, has been shown to provide a survival benefit in patients with metastatic colorectal cancers [2] and is a choice of first-line treatment for KRAS wild-type metastatic colorectal cancers [3].”
BackgroundMarkers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · PubMed · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 53
“The results of this pivotal trial lead to the approval of CTX in the frontline setting in combination with FOLFIRI in patients with KRAS WT mCRC (6,25).”
BackgroundIntegrating molecular diagnostics into anticancer drug discovery
Peták, I., Schwab, R. E., Őrfi, L., Kopper, L., & Kéri, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3135 · Cited by 61
“In a Phase II trial known as OPUS and a Phase III trial known as CRYSTAL, cetuximab was combined with first-line chemotherapy (fluorouracil, leucovorin and oxaliplatin, or irinotecan, fluorouracil and leucovorin, respectively”
MethodGhiringhelli, F., Hennequin, A., Drouillard, A., Lepage, C., Faivre, J., & Bouvier, A. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.05.011 · Cited by 62
Cell Death Signaling and Anticancer Therapy
Galluzzi, L., Vitale, I., Vacchelli, E., & Kroemer, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00005 · Cited by 64
“…cancer HNSCC CLL Colorectal cancer (metastatic) B-cell NHL Follicular lymphoma Breast cancer Nuckel et al. (2005), Jaglowski et al. (2010) Wedam et al. (2006) Van Cutsem et al. (2009), Niu et al. (2010) Cheson (2010) Hoy and Wagstaff (2006), Van Cutsem et al. (2007), Dubois and Cohen (2009) Shan…”
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Dahan, L., Norguet, E., Étienne-Grimaldi, M.-C., Formento, J., Gasmi, M., Nanni, I., Gaudart, J., Garcia, S., Ouafik, L., Seitz, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-496 · Cited by 64
Role of cMET in the Development and Progression of Colorectal Cancer
Pérez-Vargas, J. C. S., Biondani, P., Maggi, C., Gariboldi, M., Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., Bartolomeo, M. D., de Braud, F., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918056 · Cited by 64
“It is well known that therapeutic strategies for CRC have focused on the development of anti-EGFR monoclonal antibodies (MoAbs)—such as cetuximab and panitumumab [48,49].”
BackgroundKin, C., Kidess, E., Poultsides, G. A., Visser, B. C., & Jeffrey, S. S. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.811896 · Cited by 62
Solassol, J., Ramos, J., Lopez‐Crapez, E., Saifi, M., Mangé, A., Vianès, E., Lamy, P., Costes, V., & Maudelondé, T. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12053191 · Cited by 64
Sasaki, K., Margonis, G. A., Wilson, A., Kim, Y., Buettner, S., Andreatos, N., Gani, F., Amini, N., Spolverato, G., & Pawlik, T. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5361-6 · Cited by 58
Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation
Hoekstra, E., Das, A. M., Willemsen, M., Swets, M., Kuppen, P. J. K., van der Woude, C. J., Bruno, M. J., Shah, J. P., Hagen, T. L. M. T., Chisholm, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12321 · Cited by 57
“In particular, inhibitors of the Epidermal Growth Factor Receptor (EGFR), which is often over-expressed in CRC, have shown promise in this disease [2–4].”
BackgroundToledo, R. A., Cubillo, A., Vega, E., Garralda, E., Álvarez-Gallego, R., Varga, L. U. D. L., Rodríguez-Pascual, J., Sánchez, G., Sarno, F., Prieto, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13311 · Cited by 63
“However, these patients ultimately progress, at least partially because of the emergence of mutations that occur in genes in the RAS pathway during treatment [2-5].”
BackgroundOverview of precision oncology trials: challenges and opportunities
Fountzilas, E., & Tsimberidou, A. M. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1504677 · Cited by 64
Glimelius, B. L. G., & Cavalli‐Björkman, N. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.640828 · Cited by 65
“First line 0 + Cetuxi 0 + Cetuxi 0 + Cetuxi FOLFIRI (CRYSTAL) [118,119] 1198 all 39 47 8.”
MethodImpact of Genomics on Personalized Cancer Medicine
Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 65
“Similarly, patients with K-RAS mutant colon cancers do not respond to therapy with EGFR monoclonal antibodies (33, 34).”
BackgroundBrodowicz, T., Ciuleanu, T., Radosavljevic, D. Z., Shacham‐Shmueli, E., Vrbanec, D., Plāte, S., Mršić-Krmpotić, Z., Dank, M., Purkalne, G., Messinger, D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt116 · Cited by 61
PP2A-Mediated Anticancer Therapy
Chen, W., Wang, Z., Jiang, C., & Ding, Y. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/675429 · Cited by 57
“Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 675429, 10 pages http://dx.doi.org/10.1155/2013/675429”
BackgroundInfluentialImmune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 56
General principles of chemotherapy.
Ricevuto, E., Bruera, G., & Marchetti, P. (2010) · PubMed · Cited by 57
Park, E. J., Baek, J., Choi, G., Park, W. C., Yu, C. S., Kang, S., Min, B. S., Kim, J. H., Kim, H. R., Lee, B. H., et al. (2020) · Cancers · doi:10.3390/cancers12082306 · Cited by 58
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Sebio, A., Paré, L., Páez, D., Salazar, J., González, A., Sala, N., del Río, E., Martín-Richard, M., Tobeña, M., Barnadas, A., et al. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835d9b0b · Cited by 62
Saridaki, Z., Androulakis, N., Vardakis, N., Vamvakas, L., Kabouraki, E., Kalbakis, K., Hatzidaki, D., Voutsina, A., Mavroudis, D., Georgoulias, V., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.509 · Cited by 62
“In addition, other studies have also, provided evidence of the effectiveness of cetuximab addition to a doublet combination in unselected mCRC patients, in terms of PFS and OS (Bokemeyer et al, 2009; Van Cutsem et al, 2009).”
BackgroundMethodResultInfluentialRubinson, D. A., Höchster, H. S., Ryan, D. P., Wolpin, B. M., McCleary, N. J., Abrams, T. A., Chan, J. A.-W., Iqbal, S., Lenz, H., Lim, D. W., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9956-5 · Cited by 57
“Investigation of this primary resistance to EGFR inhibition demonstrated that a subset of non-responders possessed activating mutations in the KRAS oncogene allowing EGFR-independent activation of mitogenic signaling pathways [4, 6, 7].”
Deng, Y., Wang, L., Tan, S., Kim, G. P., Dou, R., Chen, D., Cai, Y., Fu, X., Wang, L., Zhu, J., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.006 · Cited by 72
In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer
Verma, S., McLeod, D., Batist, G., Robidoux, A., Martins, I., & Mackey, J. R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0278 · Cited by 56
Loupakis, F., Bria, E., Vaccaro, V., Cuppone, F., Milella, M., Carlini, P., Cremolini, C., Salvatore, L., Falcone, A., Muti, P. C., et al. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-58 · Cited by 65
“6]) and in better, but not significantly, RR (40% [24-58] vs 17% [7-23]-34) and OS (median OS: 21.”
Zhang, L., Castanaro, C., Luan, B., Yang, K., Fan, L., Fairhurst, J. L., Rafique, A., Potocky, T. B., Shan, J., Delfino, F. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1033 · Cited by 61
Pereira, D. M., Simões, A. E. S., Gomes, S. E., Castro, R. E., Carvalho, T., Rodrigues, C. M. P., & Borralho, P. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9107 · Cited by 58
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Bupathi, M., & Wu, C. S.-Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.07.03 · Cited by 61
“It has been consistently shown these individuals have a more aggressive disease and worse outcome in the adjuvant and metastatic setting (7,8).”
BackgroundText Mining for Drug Discovery
Zheng, S., Dharssi, S., Wu, M., Li, J., & Lu, Z. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9089-4_13 · Cited by 64
Precision medicine for metastatic colorectal cancer: an evolving era
Güler, İ., Aşkan, G., Klostergaard, J., & Şahin, İ. H. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1663174 · Cited by 60
“as single agents and also in combination with cytotoxic chemotherapy [4,5], including patients with wild-type kirsten rat”
BackgroundExplaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
Aderka, D., Stintzing, S., & Heinemann, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30172-x · Cited by 54
Akce, M., Farran, B., Switchenko, J. M., Rupji, M., Kang, S., Khalil, L. E., Ruggieri, A. N., Olson, B. M., Shaib, W. L., Wu, C. S.-Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007235 · Cited by 62
Cuneo, K. C., Nyati, M. K., Ray, D., & Lawrence, T. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.002 · Cited by 62
“Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.”
BackgroundInfluentialInflammation-based factors and prognosis in patients with colorectal cancer
Maeda, K., Shibutani, M., Otani, H., Nagahara, H., Ikeya, T., Iseki, Y., Tanaka, H., Muguruma, K., & Hirakawa, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i8.111 · Cited by 57
Samalin, E., Bouché, O., Thézenas, S., François, É., Adenis, A., Bennouna, J., Taïeb, J., Desseigne, F., Seitz, J. F., Conroy, T., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.813 · Cited by 57
“…Cutsem et al, 2009, 2011; Peeters et al, 2010), progression-free survival (PFS) (Cunningham et al, 2004; Hurwitz et al, 2004; Giantonio et al, 2007; Van Cutsem et al, 2009, 2011; Douillard et al, 2010; Peeters et al, 2010) and overall survival (OS) (Hurwitz et al, 2004; Giantonio et al, 2007; Van…”
BackgroundInfluentialMaeda, K., Shibutani, M., Otani, H., Nagahara, H., Sugano, K., Ikeya, T., Kubo, N., Amano, R., Kimura, K., Muguruma, K., et al. (2013) · World Journal of Surgery · doi:10.1007/s00268-013-2386-x · Cited by 56
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome
García‐Foncillas, J., & Díaz‐Rubio, E. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0551-3 · Cited by 61
“In the phase III Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial, adding cetuximab to standard FOLFIRI regimen in unselected patients with EGFR-expressing metastatic colorectal cancer signifi cantly prolonged PFS from 8.0 months to 8.9 months (p = 0.036) and in…”
InfluentialMorris, V. K., Lucas, F. A. S., Overman, M. J., Eng, C., Morelli, M. P., Jiang, Z., Luthra, R., Meric‐Bernstam, F., Maru, D. M., Scheet, P. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu252 · Cited by 58
Epidermal Growth Factor Receptor (EGFR)-RAS Signaling Pathway in Penile Squamous Cell Carcinoma
Gou, H.-F., Li, X., Qiu, M., Cheng, K., Li, L.-H., Dong, H., Chen, Y., Tang, Y., Gao, F., Zhao, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062175 · Cited by 57
Grivas, P. D., Monk, B. J., Petrylak, D. P., Reck, M., Foley, G., Guenther, S., Hennessy, D., Makris, C., & Moehler, M. H. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00665-1 · Cited by 61
Lhoumeau, A., Martinez, S., Boher, J., Monges, G. M., Castellano, R., Goubard, A., Doremus, M., Poizat, F., Lelong, B., de Chaisemartin, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123768 · Cited by 59
Sigal, J. J. (1998) · PubMed · Cited by 64
Benson, A. B., Arnoletti, J. P., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Dilawari, R. A., Engstrom, P. F., Enzinger, P. C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0104 · Cited by 66
Rosa, R., Melisi, D., Damiano, V., Bianco, R., Garofalo, S., Gelardi, T., Agrawal, S., Di Nicolantonio, F., Scarpa, A., Bardelli, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3376 · Cited by 54
Colorectal Cancer Biomarkers in the Era of Personalized Medicine
Patel, J. N., Fong, M. K., & Jagosky, M. H. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010003 · Cited by 59
“In the CRYSTAL trial, KRAS wild-type patients were randomized to FOLFIRI alone or FOLFIRI with cetuximab and in the FIRE-3 trial, a similar population of patients was randomized to FOLFIRI with cetuximab vs FOLFIRI with bevacizumab [12,13].”
MethodCurcumin: A therapeutic strategy for colorectal cancer?
de Porras, V. R., Layos, L., & Martinez‐Balibrea, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.004 · Cited by 61
von Weikersthal, L. F., Schalhorn, A., Stauch, M. B., Quietzsch, D., Maubach, P. A., Lambertz, H., Oruzio, D. V., Schlag, R., Weigang-Köhler, K., Vehling-Kaiser, U., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.022 · Cited by 58
Argilés, G., Saunders, M. P., Rivera, F., Sobrero, A., Benson, A., Guillén Ponce, C., Cascinu, S., Van Cutsem, E., Macpherson, I. R., Strumberg, D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.013 · Cited by 54
“Of note, discontinuation of all study treatment (chemotherapy and regorafenib) as a result of TEAEs only occurred in four patients, with most patients continuing at least one component of study treatment [9,12–16].”
BackgroundResultSelf-citationSchwarz, R. E., Berlin, J. D., Lenz, H., Nordlinger, B., Rubbia‐Brandt, L., & Choti, M. A. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00558.x · Cited by 58
Hagman, H., Frödin, J., Berglund, Å., Sundberg, J., Vestermark, L. W., Albertsson, M., Fernebro, E., & Johnsson, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv490 · Cited by 56
Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
Taïeb, J., Balogoun, R., Malicot, K. L., Tabernero, J. M., Mini, E., Folprecht, G., Laethem, J. V., Emile, J.-F., Mulot, C., Fratté, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw687 · Cited by 57
“Previous trials of anti-EGFR therapies combined with irinotecan or oxaliplatin-containing regimens showed no benefit in patients with KRAS exon 2 mutations [2, 6].”
BackgroundSelf-citationChu, P., Lin, P., Wu, H.-Y., Lin, K., Wu, C. S.-Y., Bekaii‐Saab, T., Lin, Y., Lee, C., Lee, J.-C., & Chen, C. (2018) · Oncogene · doi:10.1038/s41388-018-0222-3 · Cited by 59
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 55
“CRYSTAL was a randomised phase 3 trial that investigated the addition of the anti-EGFR monoclonal antibody cetuximab to first-line FOLFIRI chemotherapy.[28-30] Cetuximab was associated with significantly improved PFS (9.”
MethodMa, M., Wang, X., Liu, N., Shan, F., & Feng, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106388 · Cited by 62
EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging
Zhou, J., Joshi, B. P., Duan, X., Pant, A., Qiu, Z., Kuick, R. D., Owens, S. R., & Wang, T. D. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.28 · Cited by 59
“receptor has an important role in the development of a number of epithelial-derived cancers,(15) and it is an important target for CRC therapy.(16,17) Overexpression of EGFR has been”
BackgroundVelenik, V., Ocvirk, J., Oblak, I., & Anderluh, F. (2009) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2009.12.002 · Cited by 59
“Data from randomized studies in mCRC patients suggest that tumor KRAS mutational status is predictive for response to cetuximab in combination with chemotherapy.(16,17) In rectal cancer patients treated with cetuximabbased therapy, the frequency of TRG3-4 was reported to be higher (58% vs.”
BackgroundTrial Watch: Radioimmunotherapy for oncological indications
Bloy, N., Pol, J. G., Manic, G., Vitale, I., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954929 · Cited by 56
Levin-Sparenberg, E., Bylsma, L. C., Lowe, K. A., Sangaré, L. R., Fryzek, J. P., & Alexander, D. D. (2020) · Gastroenterology Research · doi:10.14740/gr1167 · Cited by 60
“Numerous studies now show that mutations in codon 12 or 13 of exon 2 of the KRAS gene render tumors essentially insensitive to treatment with EGFR inhibitors [8-17], while anti-EGFR therapies have demonstrated a clear clinical benefit in patients with RAS wildtype (WT) mCRC [8, 18, 19].”
BackgroundMolecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
Li, F., Lin, Y., Li, R., Shen, X., Xiang, M., Xiong, G., Zhang, K., Xia, T., Guo, J., Miao, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1165666 · Cited by 60
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 65
Liu, Z., Ma, T., Liu, H., Jin, Z., Sun, X., Zhao, H., Shi, J., Jia, B., Li, F., & Wang, F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp4005047 · Cited by 57
Consequences of chemotherapy on resection of colorectal liver metastases
Pessaux, P., Chenard, M., Bachellier, P., & Jaeck, D. (2010) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2010.06.004 · Cited by 54
Linardou, H., Briasoulis, E. C., Dahabreh, I. J., Mountzios, G., PAPADIMITRIOU, C. A., Papadopoulos, S., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.008 · Cited by 56
Troiani, T., Zappavigna, S., Martinelli, E., Addeo, S. R., Stiuso, P., Ciardiello, F., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.756469 · Cited by 53
“[16].”
Fiore, F. D., Rigal, O., Ménager, C., Michel, P., & Pfister, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.507 · Cited by 53
Sidhu, R., Rong, A., & Dahlberg, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2502 · Cited by 59
“Van Cutsem et al, 2009 (9) FOLFIRI vs.”
BackgroundTargeted therapies in gastroesophageal cancer
Kasper, S., & Schüler, M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.009 · Cited by 54
“Cetuximab (chimeric immunoglobulin G (IgG1)) and panitumumab (human IgG2) were the first anti-EGFR moAbs approved for the treatment of metastatic colorectal cancer based on activity as single agents and in combination with chemotherapy [9,16,21,55,80,81].”
BackgroundBachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 56
“Cetuximab, 400/250 mg/m(2)[11] FOLFIRI CRC 600 – 16 – – – 20 – – 2.”
Targeted treatments in colorectal cancer: state of the art and future perspectives
Arnold, D., & Seufferlein, T. (2010) · Gut · doi:10.1136/gut.2009.196006 · Cited by 64
“However, PFS was not improved. In contrast, the combination of cetuximab with the FOLFIRI protocol (the CRYSTAL trial) resulted in a significant improvement of both the PFS (median PFS from 8 to 8.9 months; HR 0.851, 95% CI 0.726 to 0.998) and ORR (39% vs 47%; p=0.004) (”
BackgroundInfluentialIshiguro, M., Watanabe, T., Yamaguchi, K., Satoh, T., Ito, H., Seriu, T., Sakata, Y., & Sugihara, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys005 · Cited by 58
MacConaill, L. E., Van Hummelen, P., Meyerson, M., & Hahn, W. C. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0110 · Cited by 54
Cappuzzo, F., Sacconi, A., Landi, L. M., Ludovini, V., Biagioni, F., D’Incecco, A., Capodanno, A., Salvini, J., Corgna, E., Cupini, S., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.11.006 · Cited by 58
Adverse kidney effects of epidermal growth factor receptor inhibitors
Izzedine, H., & Perazella, M. A. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw467 · Cited by 56
Pugh, S. A., Thiébaut, R., Bridgewater, J. A., Grisoni, M.-L., Moutasim, K. A., Rousseau, F., Thomas, G. J., Griffiths, G. O., Liebaert, F., Primrose, J. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21291 · Cited by 55
“com/oncotarget advanced colorectal cancer, [1-4] its role was evaluated as an adjunct to chemotherapy and surgery for operable colorectal liver metastases in the New EPOC study.”
BackgroundKim, H. K., Lee, I.-K., Bang, H., Kim, H. C., Lee, W. Y., Yun, S. H., Lee, J., Lee, S. J., Park, Y. S., Kim, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0535 · Cited by 60
“The survival of metastatic CRC has been markedly improved in the past decades resulting from the development of targeted therapies such as cetuximab, panitumumab, bevacizumab, and regorafenib (2-6).”
BackgroundRecent advances in treatment for colorectal liver metastasis
Oki, E., Ando, K., Nakanishi, R., Sugiyama, M., Nakashima, Y., Kubo, N., Kudou, K., Saeki, H., Nozoe, T., Emi, Y., et al. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12071 · Cited by 54
PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+γδ Treg polarization
Zhan, Y., Zheng, L., Liu, J., Hu, D., Wang, J., Liu, K., Guo, J., Zhang, T., & Kong, D. (2021) · JCI Insight · doi:10.1172/jci.insight.148028 · Cited by 58
Montagnani, F., Chiriatti, A., Turrisi, G., Francini, G., & Fiorentini, G. (2010) · Colorectal Disease · doi:10.1111/j.1463-1318.2010.02206.x · Cited by 61
Inhibition of SLC1A 5 sensitizes colorectal cancer to cetuximab
Ma, H., Wu, Z., Peng, J., Li, Y., Huang, H., Liao, Y., Zhou, M., Sun, L., Huang, N., Shi, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31274 · Cited by 52
“For patients with metastatic CRC (mCRC), the typical therapeutic regiments for first-line and secondline are combined employments with fluoropyrimidine (FOLFIRI/CAPIRI or FOLFOX/CAPOX) and biologic molecular agents targeting the epidermal growth factor receptor (EGFR) (cetuximab or panitumumab) or angiogenesis (bevaci…”
BackgroundKato, S., Schwaederlé, M. C., Fanta, P. T., Okamura, R., Leichman, L., Lippman, S. M., Lanman, R. B., Raymond, V. M., Talasaz, A., & Kurzrock, R. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00158 · Cited by 52
Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 59
Targeting the RAS-dependent chemoresistance: The Warburg connection
Serna-Blasco, R., Sanz-Álvarez, M., Aguilera, Ó., & García-Foncillas, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.016 · Cited by 52
Russo, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 63
Wang, W., Zhao, Z., Ma, S., Yu, G., Liu, B., Zhang, L., Zhang, W., Kulkarni, A. B., Sun, Z., & Zhao, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119723 · Cited by 57
“Cetuximab is a chimeric IgG1 monoclonal antibody that is currently licensed for the treatment of HNSCC patients [11, 12].”
BackgroundYou, B., & Chen, E. X. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010395940 · Cited by 57
“In addition, the European medicine agency has approved cetuximab given in combination with standard chemotherapy in previously untreated patients.(7,72,74) It is important to note that anti-EGFR mAbs have not shown significant improvements in overall survival when they are combined with standard chemotherapy in metast…”
BackgroundIndian Council of Medical Research consensus document for the management of colorectal cancer
Sirohi, B., Shrikhande, S. V., Perakath, B., Raghunandharao, D., Julka, P. K., Lele, V. R., Chaturvedi, A., Nandakumar, A., Ramadwar, M. S., Bhatia, V., et al. (2014) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/0971-5851.142031 · Cited by 54
“RAS mutation testing is recommended for patients with metastatic disease as mutations in the RAS gene predict a lack of response to therapy with cetuximab and panitumumab[3,4,5] BRAF mutation testing is currently not recommended.”
BackgroundGarrido-Laguna, I., Hong, D. S., Janku, F., Nguyen, L. M., Falchook, G. S., Fu, S., Wheler, J. J., Luthra, R., Naing, A., Wang, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038033 · Cited by 52
Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, A. G., Rouleau, T., Cooksley, C. D., Halm, J. K., Vithala, M. V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1821-8 · Cited by 60
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.